Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor

• Leena Karimi,
• Carla L. Alves,
• Mikkel G. Terp,
• Martina Tuttolomondo,
• Neil Portman,
• Sidse Ehmsen,
• Lene E. Johansen,
• Martin Bak,
• Elgene Lim,
• Henrik J. Ditzel

Affiliations

Leena Karimi

Department of Cancer and Inflammation Research Institute of Molecular Medicine University of Southern Denmark Odense Denmark

Carla L. Alves

Department of Cancer and Inflammation Research Institute of Molecular Medicine University of Southern Denmark Odense Denmark

Mikkel G. Terp

Department of Cancer and Inflammation Research Institute of Molecular Medicine University of Southern Denmark Odense Denmark

Martina Tuttolomondo

Department of Cancer and Inflammation Research Institute of Molecular Medicine University of Southern Denmark Odense Denmark

Neil Portman

Garvan Institute of Medical Research Darlinghurst Sydney New South Wales Australia

Sidse Ehmsen

Department of Cancer and Inflammation Research Institute of Molecular Medicine University of Southern Denmark Odense Denmark

Lene E. Johansen

Department of Cancer and Inflammation Research Institute of Molecular Medicine University of Southern Denmark Odense Denmark

Martin Bak

Department of Pathology Sydvestjysk Sygehus Esbjerg Denmark

Elgene Lim

Garvan Institute of Medical Research Darlinghurst Sydney New South Wales Australia

Henrik J. Ditzel

Department of Cancer and Inflammation Research Institute of Molecular Medicine University of Southern Denmark Odense Denmark